Abstract:Objective To investigate the short-term efficacy and safety of domestic rituximab (Hanlikang?) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Methods The clinical data of 14 newly diagnosed DLBCL patients who were definitely diagnosed and treated with domestic rituximab-based chemotherapy in the Department of Hematology, the Second Affiliated Hospital of Anhui Medical University from July 2019 to March 2021 were collected. The clinical efficacy was evaluated after 3-4 courses of chemotherapy. Adverse events were evaluated in each chemotherapy course. The level of peripheral blood immunoglobulin G (IgG) and the percentage of CD20⁺B lymphocytes were detected before and after chemotherapy. Results All patients received 3-8 courses of chemotherapy, with a median chemotherapy cycle of 6 courses. After 3-4 courses of chemotherapy, 7 patients (50%) had complete remission and 6 patients (42.9%) had partial remission, and the overall response rate was 92.9%. All patients did not have acute infusion reaction and gastrointestinal adverse reaction, only one patient had transient atrial tachycardia during the first chemotherapy, and one patient had elevated transaminase. There were 10 patients with hematological toxicity of different degrees during the treatment, including 2 cases of grade 4 bone marrow suppression, which were reversed and relieved after active symptomatic treatment. The median of CD20⁺B lymphocytes in the peripheral blood of 9 patients before and after chemotherapy was 11.6% and 0.0% respectively, with a statistically significant difference (Z=2.666, P=0.008). The median of IgG level in the peripheral blood of 11 patients before and after chemotherapy was 10.35 g/L and 8.56 g/L respectively, with a statistically significant difference (Z=2.312, P=0.021). Conclusion The chemotherapy regimen based on domestic rituximab has better short-term efficacy and safety in the treatment of newly diagnosed DLBCL, which is more economical than the original rituximab, and the changes of peripheral blood IgG and CD20⁺B lymphocytes also reflect the targeted therapeutic effect of domestic rituximab.